Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Online trio: Strong profits, no debt


Bookmark and Share
by Andy Obermueller, editor Fast-Track Millionaire

Andy ObermuellerIn my latest screen, I looked for profitable and debt-free U.S. companies with a market cap of $900 million to $1 billion.

Here's a look at three Internet related stocks that made my list: Shutterfly (SFLY), Sourcefire (FIRE), and LogMeIn (LOGM).

Shutterfly is a website that lets users print photos as paper photographs or to include the image on a variety of items, like coffee mugs and calendars.

Its business is highly cyclical, as you can imagine, with the December holidays accounting for the lion's share of the revenue. Even so, the year-over-year top-line is impressive, at 58.7% from 2010 to 2011.

The company does nicely on the bottom line as well, at 13.3%. The growth and profitability show up right where they should: In the shareholder equity line on the balance sheet, which has doubled in the past year.
Advertisement
Banner

The kicker is that not only is this company debt-free, it's asset rich. It has $180 million in cold, hard cash. Look for it to deploy this capital with robust advertising, business expansion and, potentially, acquisitions. This company is a strong long-term play. I like it at its current price.

Sourcefire is a network defense company. This is a sector that many are predicting strong growth in as more and more companies seek to safeguard the data stored in their computers.

Sourcefire has a nice top-line growth trend that amounts to a 30.5% compound annual growth rate and a smokin' high P/E.

But the intrusion prevention market was about $1.5 billion in 2010 and is projected to grow to $2.1 billion in 2014 and Sourcefire has what looks like an 8% market share, so it can continue to grow indefinitely.

One reason to be confident in that is the company's history. It was founded by Martin Roesch, a bona fide computer genius who wrote the protocol for intrusion detection. (It's called Snort.)

Roesch has now built a commercial version of the software in response to industry demand and It is clearly a leader. There's nothing not to like about its financials. Its industry position is strong, too. I like this company for a multiyear holding period.

LogMeIn has software that lets you access your computer remotely.  It's very good technology that addresses a real need in today's world -- mobility.

In the old days, I went into the office; now, my workplace is everywhere, which affords me far more flexibility while also cutting costs for the company. More and more companies are discovering this win-win approach.

And LOGM, with a 21% net margin and a 55% compound annual growth rate, is clearly taking a leading position in filling the need. Long-term prospects are favorable. This is a great company for a general growth portfolio.

Learn more about this financial newsletter at Andy Obermueller's Fast-Track Millionaire.


Related articles:

Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary